Project Grant R44AI192013
Award Date 9/19/25
Completion Date 8/31/27
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand how exposure to food antigens leads to the formation of regulatory T cells and hyporesponsive conventional T cells in the gut. The $553,342 award to the Regents of the University of Minnesota will be used to study the underlying mechanisms, with the goal of identifying potential therapies for...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $4,239,889.00 to support the development of an oral enzymatic therapy adjunctive to the dietary management of celiac disease. The award is granted to Enteralia Bioscience LLC, located in Holden, MA, and has a performance period from Jul 1, 2024 to Jun 30, 2027. The overall objective of this research initiative is to develop an innovative oral...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $306,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Qrono, Inc., a for-profit medical research and development company. The grant funding supports the development of QR402, a first-in-class, oral nanomedicine that uses an AMPK pathway agonist to target intestinal dendritic cells and restore immunological tolerance as a preventative therapy for type 1 diabetes. The goal is to...
- This $314,347 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund the development of a lipid nanoparticle (LNP) delivery system using a proprietary polyethylene glycol (PEG) alternative called poly(oligoethylene glycol) methyl ether methacrylate (POEGMA) as a PEG-free carrier for mRNA payloads. The goal is to address concerns around anti-PEG antibodies, PEG allergies, and...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $300,000 Phase I SBIR grant to Optimeos Life Sciences, Inc. to develop an off-the-shelf nanoparticle platform for in vivo stem cell gene therapy to treat primary immunodeficiencies. The project aims to deliver a DNA payload in nanoparticles targeting hematopoietic stem and progenitor cells for gene replacement, with the initial focus on treating...
- This federal Project Grant award of $350,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop polymer-derived biomaterials for messenger RNA (mRNA) delivery to induce antigen-specific immune tolerance. The award supports research to evaluate diverse nanocarrier formulations encapsulating antigens and mRNAs encoding tolerogenic proteins, investigate the biodistribution and...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $501,011.00 to the University of North Carolina at Chapel Hill to conduct research on biodegradable polymeric microparticles comprised of acetalated dextran and their ability to induce immune tolerance. The goal is to develop an antigen-specific tolerance therapy for autoimmune diseases, an alternative to general...
- This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a GMP-compliant E. coli dihydrofolate reductase (EDHFR) vector. This vector will be used to monitor the biodistribution and trafficking of investigational chimeric antigen receptor (CAR) T cell therapies through positron emission tomography (PET) imaging. The goals are to provide a...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $919,501 to Emmune Inc. to develop a non-viral gene therapy platform for delivering the ECD4-IG therapeutic protein as a potential lifetime treatment for HIV. The key products and services funded under this 1-year award include conducting basic science experiments to inform the development of this...
- This $307,091 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of immune evasion technologies by Aleutian Therapeutics, Inc. to enable allogeneic cell therapies without the need for immunosuppressive drugs. The objective is to determine the minimum number of genetic edits required to allow human pluripotent stem cell-derived therapies to overcome immune rejection barriers like...